Inhaled nitric oxide (iNO) reduces pulmonary vascular resistance by preferential vasodilation in ventilated lung units. In experimental animals, iNO also reduces airway resistance by smooth muscle relaxation. Hence, there may be a therapeutic role for iNO in evolving bronchopulmonary dysplasia (BPD).
INTRODUCTION
Bronchopulmonary dysplasia (BPD), a common condition affecting premature neonates, is an important cause of long-term respiratory morbidity. BPD is characterized by reduced lung compliance (C L ), elevated pulmonary resistance (R L ), areas of altered ventilation-perfusion (V A /Q) relationship, lung inflammation and varying degrees of pulmonary hypertension. [1] [2] [3] [4] Inhaled nitric oxide (iNO) relaxes vascular smooth muscle and is used to treat infants with persistent pulmonary hypertension and hypoxemic respiratory failure. 5 iNO can reduce extrapulmonary right to left shunt and improve V A /Q matching due to selective relaxation of the pulmonary vasculature in ventilated lung areas. 6 Data indicate reduced intrapulmonary right to left shunt and improved oxygenation even in the absence of extrapulmonary shunt. 7, 8 Data suggest that low doses of iNO are as effective in improving oxygenation as higher doses. 9 Animal data suggest that iNO modulates airway smooth muscle contractility in methacholine-induced bronchoconstriction 10, 11 and in newborn piglets. 12 Thus, iNO may improve ventilation distribution and decrease gas trapping by reducing airway obstruction in infants with BPD, as well as decrease physiological dead space as described in a model of respiratory distress syndrome. 8 Anti-inflammatory properties of iNO 13 also suggest a therapeutic role in BPD.
Studies of iNO demonstrated beneficial effects on oxygenation in infants with BPD. [14] [15] [16] Severe BPD is often complicated by pulmonary hypertension, right ventricular (RV) hypertrophy and cor-pulmonale. A reduction in pulmonary vascular resistance by iNO may improve RV function, but unconfirmed data suggest negative inotropic effects on left ventricular (LV) function.
The objective of this study was to evaluate the acute effects of low-dose iNO on lung mechanics, ventilation distribution, oxygenation and cardiac function in preterm infants with evolving BPD. It was hypothesized that low-dose iNO would reduce R L , increase C L , improve ventilation distribution, improve oxygenation and improve RV function.
METHODS

Study Population
Mechanically ventilated preterm infants with established BPD or those with evolving BPD, based on oxygen and ventilator dependence beyond 14 days of postnatal age were eligible for enrollment. Inclusion criteria were: birth weight 500 to 1500 g, fraction of inspired oxygen (FiO 2 ) Z0.25 in order to maintain arterial oxygen saturation (SpO 2 ) greater than 90% while on mechanical ventilation. Exclusion criteria were: corticosteroid administration within 72 hours of the study, thrombocytopenia (platelet count <100,000/mm 3 ) or any bleeding diathesis, intracranial hemorrhage ZGrade III by Papile's classification, congenital cardiopulmonary anomaly, clinically significant patent ductus arteriosus and documented septicemia. Infants deemed unstable by the attending neonatologist were not studied.
The study was conducted at the University of Miami, Jackson Memorial Medical Center and approved by the University of Miami Subcommittee for the Protection of Human Subjects. A written informed consent was obtained from the parents or legal guardian of each enrolled infant. It was estimated that enrollment of at least 13 infants was needed to detect a 30% change in airway resistance with a 35% SD, at an alpha of 5% and a power of 80%.
Study Protocol
Infants were studied in the supine position while in their incubators and ventilated with settings determined by the clinical team. Initially, an echocardiographic examination was performed by two-dimensional and color-flow Doppler (Model SSA-380A, Toshiba America Medical Systems, Tustin, CA). Subsequently, a 1-hour baseline recording was obtained while the infants were left undisturbed. This was followed by a multiple-breath nitrogen (N 2 ) washout with 100% oxygen for 20 to 25 mechanical breaths that was repeated three times to assess ventilation distribution. During each N 2 washout, the mechanical rate was transiently increased to over-ride spontaneous breathing and obtain a uniform V T .
After baseline recordings were completed, infants received iNO at 10 parts per million (ppm) during 2 hours using a concentrationregulated delivery system (I-NO VENT, Datex-Ohmeda Inc., Madison, WI) into the inspiratory limb of the ventilator circuit. NO and NO 2 levels in the inspired gas were monitored.
Three multiple-breath N 2 washouts were performed at the end of the first and the second hour of iNO administration (1 hour iNO, 2 hour iNO). At the end of 2 hour iNO, the echocardiographic evaluation was repeated while breathing iNO. Subsequently, iNO was weaned initially to 5 ppm, followed by step reductions of 1 ppm. Weaning procedure allowed continuation of iNO if SpO 2 remained consistently below 88%.
Specific Measurements
Measurements during baseline, 1 hour iNO, 2 hour iNO periods included airflow measured by a pneumotachograph previously calibrated against a mass flowmeter (Matheson, Secaucus, NJ). Tidal volume (V T ) was obtained from digital integration of airflow signal. Airway pressure (P AW ) was measured at the endotracheal tube connector and esophageal pressure (P ES ) was measured at the lower esophagus using a 5 French water-filled feeding tube. P AW and P ES were obtained by pressure transducers (Transpac 42586 Abbot Critical Care, North Chicago, IL) connected to medical grade transducer couplers (Gould instruments, Valley View, OH) and calibrated by water manometry. An end-expiratory occlusion was performed to validate P ES and the feeding tube was flushed periodically. SpO 2 was measured by pulse oximetry (Oxypleth 520-A, Novametrix medical systems Inc., Wallingford, CT). FiO 2 was measured using an O 2 analyzer (Vascular Technology Inc, Chelmsford, MA). Transcutaneous CO 2 tension (TcPCO 2 ) was measured using a Transcend II monitor (Sensormedics, Yorba Linda, CA). N 2 concentration was measured side-stream using a precalibrated N 2 analyzer (505 Nitralyzer, Med Science, Saint Louis, MO) at the ET tube adapter. This analyzer samples gas at 3 ml/ min, with a ±1% accuracy and 0.05 seconds typical response time. All signals were digitized at 100 Hz and recorded into a personal computer for offline analysis. Vital parameters were monitored by a neonatal monitor (model 91416, Spacelabs Medical, Redmond, WA). Cranial ultrasound results were abstracted from clinical records before and after the study on all infants.
Data Analysis
Computer-aided analysis was used to obtain C L and R L using the Mead and Wittenberger method 19 from at least 15 mechanical breaths. Ventilation distribution was assessed by quantitative evaluation by N 2 clearance delay and volume. 20 The N 2 concentration in exhaled gas and exhaled V T of each breath during a multiple-breath N 2 washout were measured. The total exhaled volume for the end-expiratory N 2 concentration to decrease to 50% of the initial value during the N 2 washout (V E to 50% decrease in end-expiratory N 2 ) was obtained as the sum of exhaled V T . Mean values for V E to 50% end-expiratory N 2 were calculated during baseline, and after 1 and 2 hours of iNO.
Oxygenation was assessed as mean SpO 2 and FiO 2 over baseline, 1 hour iNO and 2 hour iNO. The ratio of SpO 2 /FiO 2 was calculated over time as an oxygenation index. Episodes of hypoxemia were defined as SpO 2 <85% for more than 5 seconds. The frequency and duration of hypoxemic episodes and the percentage of time spent in hypoxemia were also calculated. Hypoxemic episodes lasting more than 30 seconds were treated with a 0.1 increase in FiO 2 every 20 seconds until SpO 2 was equal or higher than 90%. FiO 2 was reduced if SpO 2 increased above 96%. Median SpO 2 and FiO 2 over each period were obtained to avoid the impact of hypoxemic episodes on mean SpO 2 and the transient increases on the mean FiO 2 .
Echocardiographic evaluation at baseline and at the end of 2 hour iNO was performed by the same investigator. In the presence of significant tricuspid regurgitation (TR), indirect quantitative estimation of systolic pulmonary artery pressure (SPAP) was derived from the TR jet velocity with the modified Bernoulli's equation: SPAP ¼ 4 Â (TR velocity) 2 þ CVP. Central venous pressure (CVP) was assumed to have a standard value of 5 mmHg. TR jets were recorded using continuous-wave Doppler echocardiography aided by color-flow mapping. Color-flow Doppler sonography was used for qualitative assessment of extrapulmonary shunt at the ductus arteriosus and foramen ovale. LV systolic function was assessed by the LV ejection fraction (LVEF) with the modified biplane Simpson's method and the RV shortening fraction (RVSF) using the apical area fractional shortening method. 21 Within-subject comparisons between the baseline, 1 hour iNO and 2 hour iNO were carried out by repeated measures analysis of variance (RM ANOVA) or Friedman's ANOVA on ranks as appropriate. Paired t-test or Wilcoxon-signed ranked test was used for paired comparisons between baseline and iNO exposure periods. A p-value <0.05 was considered significant.
RESULTS
Patient Characteristics
In all, 13 ventilated preterm infants with mean ± SD (range) birth weight 664±116 (525 to 980) g and a gestational age of 24. 9±1.2 (24 to 27) weeks were studied. Eight infants were male. Their postnatal age was 32 Lung Function C L increased slightly during the first hour of iNO but returned to baseline values in the second hour. R L was elevated at baseline, which is characteristic of infants with BPD. R L did not differ during iNO. There were no changes in N 2 clearance volume during iNO compared to baseline (Table 1) .
Cardiac Function
Baseline echocardiography results were normal in all infants except one who showed a moderate size PDA. The mean heart rate was unchanged and no infant had systemic hypotension during iNO. There was a small but significant improvement in LVEF at 2 hour iNO, but there was no significant effect on RVSF (Table 2) . TR was significant in two infants and enabled SPAP estimation. In both infants, SPAP was lower after 2 hours of iNO (20.4 vs 11.9 mmHg during baseline and 2 hour iNO, respectively).
Oxygenation
Mean and median FiO 2 did not differ during iNO from baseline. A slight reduction in FiO 2 was observed during the 1 hour iNO, which correlated with slight improvement in median SpO 2 . The mean SpO 2 /FiO 2 ratio was slightly but not consistently higher with iNO.
The frequency of hypoxemic episodes was not different between baseline and iNO, but the average duration of the hypoxemic episodes was longer during 2 hour iNO. As a result, the percent time spent in the hypoxemic range (SpO 2 <85%) was longer during 2 hour iNO. TcPCO 2 levels did not differ (Table 3) .
All infants were weaned off from iNO within 30 minutes and remained at their basal FiO 2 . All infants required supplemental oxygen therapy for at least 28 days during their hospital stay. Head ultrasonography after the study did not reveal changes compared to prior results. All infants were discharged alive.
DISCUSSION
In this study, low-dose iNO did not have acute effects on lung mechanics and ventilation distribution, which were expected to improve due to iNO-mediated relaxation of the airways. R L did not change with iNO and C L increased slightly during the first hour of iNO. These findings coincide with reports wherein iNO did not alter lung mechanics in infants with RSV bronchiolitis and history of BPD 22 or in infants with PPHN whose oxygenation improved. 23 The elevated R L in these infants may be in part due to airway damage and inflammation, 24 hence the role of airway smooth muscle relaxation in reducing R L may be smaller, which could in part explain the lack of effect of iNO. This may also be in part due to insufficient dosage as animal experiments showed dosedependent effects of iNO on bronchodilation. 10, 11 Moreover, data from healthy humans with induced bronchoconstriction 25 and asthma 26 suggests that iNO bronchodilation in humans may be weaker than in animal species.
Ventilation distribution assessed by N 2 clearance was not altered by iNO, which correlates with the unchanged R L . However, this may also be explained by data suggesting the predominant effect of iNO on the central airways.
11
This data did not show an acute improvement in oxygenation during iNO. Although this may be due to the short duration, it may also be in part due to variations in iNO dosage dependency in BPD infants.
14 iNO administration for 72 hours decreased FiO 2 in severe BPD 15 as well as in early stages of BPD. 27 While 4 days of iNO administration did not improve oxygenation in evolving BPD 28 and brief administration of high concentration of iNO (80 ppm) did not improve oxygenation in mild BPD. 29 The lack of effect of iNO on oxygenation in these infants with evolving BPD may also be explained by a relatively well-preserved lung perfusion and absence of severe pulmonary hypertension. This may account for the difference in effect compared to infants with severe BPD and high oxygen need.
It is possible that an improvement in oxygenation during the second hour of iNO may have been masked by the increased duration of hypoxemic episodes. This is unlikely to be related to study procedures since episode frequency was not altered. The increased duration of these episodes suggests that iNO may have altered the ability to match V A /Q. Hypoxemic episodes in ventilated infants are often triggered by changes in tidal and lung volume 30 and iNO could abolish the hypoxia-induced vasoconstriction in lung areas that become poorly ventilated, leading to intrapulmonary shunt and prolongation of hypoxemia. This warrants further investigation. In dogs, 31 oxygenation worsened during iNO when perfusion increased in normal or poorly ventilated areas of the lung. The response in oxygenation to iNO in chronic obstructive pulmonary disease varies 32 and oxygenation worsens in patients with areas of low V A /Q ratio due to elimination of hypoxic vasoconstriction. 33 The improved LV function during iNO may be due to a better preload and filling from an increased pulmonary blood flow, but it may also be influenced by circulating nitrosothiol metabolites 34 that can influence vasomotor tone and LV function. 35 It is unclear if this improvement is clinically significant. Although iNO is bound and inactivated by hemoglobin, there are potential side effects on the myocardium. 36, 37 In this study, there were no deleterious effects of iNO on LV function, in agreement with reports from healthy adults, 18 neonates with PPHN, 38 patients with LV assist 39 and endotoxemic animals. The statistical power of some of the comparisons in the present study was below 80%, therefore caution is recommended in their interpretation. However, there were no trends indicating the existence differences that did not reach significance due to a small sample size.
In summary, exposure to low-dose iNO had no acute effects on lung function and oxygenation in a group of ventilated preterm infants with evolving BPD. The longer duration of hypoxemic episodes during iNO may not be of clinical significance, but it should be further investigated. The slight improvement in LVEF, probably as a result of better filling, needs to be confirmed. This study does not address the possible beneficial or detrimental effects of prolonged administration of iNO in infants with BPD.
